Unknown

Dataset Information

0

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).


ABSTRACT: The four dengue virus serotypes (DENV1-4) infect several hundred million people each year living in tropical and sub-tropical regions. Clinical development of DENV vaccines is difficult because immunity to a single serotype increases risk of severe disease during a second infection with a new serotype. Leading vaccines are based on tetravalent formulations to induce simultaneous and balanced protective immunity to all 4 serotypes. TAK-003 is a tetravalent live attenuated dengue vaccine candidate developed by Takeda Vaccines Inc, which is currently being evaluated in phase 3 efficacy trials. Here, we use antibody depletion methods and chimeric, epitope transplant DENVs to characterize the specificity of neutralizing antibodies in dengue-naïve adults and non-human primates immunized with TAK-003. Our results demonstrate that TAK-003 induced high levels of DENV2 neutralizing antibodies that recognized unique (type-specific) epitopes on DENV2. In contrast, most vaccinated subjects developed lower levels of DENV1, DENV3 and DENV4 neutralizing antibodies that mainly targeted epitopes that were conserved (cross-reactive) between serotypes. Trial Registration: ClinicalTrials.gov NCT02425098.

SUBMITTER: White LJ 

PROVIDER: S-EPMC7990299 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9907483 | biostudies-literature
| S-EPMC10077010 | biostudies-literature
2016-05-10 | GSE72430 | GEO
| S-EPMC9704433 | biostudies-literature
| S-EPMC6684763 | biostudies-literature
| S-EPMC4689971 | biostudies-literature
| S-EPMC6392503 | biostudies-literature
| S-EPMC10583633 | biostudies-literature
| S-EPMC5355209 | biostudies-other
| S-EPMC5972589 | biostudies-literature